NYSE:MRK - Merck & Co., Inc. Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$69.06 +0.21 (+0.31 %)
(As of 08/19/2018 03:48 PM ET)
Previous Close$69.06
Today's Range$68.70 - $69.2350
52-Week Range$52.83 - $69.24
Volume7.84 million shs
Average Volume11.32 million shs
Market Capitalization$178.14 billion
P/E Ratio17.35
Dividend Yield2.85%
Beta0.8
Merck & Co., Inc. logoMerck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, and Premier Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:MRK
CUSIP58933Y10
Phone908-740-4000

Debt

Debt-to-Equity Ratio0.61
Current Ratio1.33
Quick Ratio1.04

Price-To-Earnings

Trailing P/E Ratio17.35
Forward P/E Ratio16.17
P/E Growth2.28

Sales & Book Value

Annual Sales$40.12 billion
Price / Sales4.64
Cash Flow$5.9740 per share
Price / Cash11.56
Book Value$12.69 per share
Price / Book5.44

Profitability

EPS (Most Recent Fiscal Year)$3.98
Net Income$2.39 billion
Net Margins3.67%
Return on Equity32.68%
Return on Assets13.02%

Miscellaneous

Employees69,000
Outstanding Shares2,696,190,000
Market Cap$178.14 billion

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 24th. Shareholders of record on Monday, September 17th will be given a dividend of $0.48 per share on Friday, October 5th. This represents a $1.92 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Friday, September 14th. View Merck & Co., Inc.'s Dividend History.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. declared that its Board of Directors has initiated a stock buyback plan on Saturday, December 2nd 2017, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Friday, July, 27th. The company reported $1.06 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.03 by $0.03. The business earned $10.47 billion during the quarter, compared to the consensus estimate of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. Merck & Co., Inc.'s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 earnings per share. View Merck & Co., Inc.'s Earnings History.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, October, 26th 2018. View Earnings Estimates for Merck & Co., Inc..

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Friday, July, 27th. The company provided EPS guidance of $4.22-4.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.24. The company issued revenue guidance of $42-42.8 billion, compared to the consensus revenue estimate of $42.12 billion.

What price target have analysts set for MRK?

17 brokerages have issued 12-month price objectives for Merck & Co., Inc.'s stock. Their predictions range from $58.83 to $77.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $66.3887 in the next year. This suggests that the stock has a possible downside of 3.9%. View Analyst Price Targets for Merck & Co., Inc..

What is the consensus analysts' recommendation for Merck & Co., Inc.?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..

Who are some of Merck & Co., Inc.'s key competitors?

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)
  • Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)
  • Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)
  • Ms. Rita A. Karachun, Principal Accounting Officer, Sr. VP of Fin. & Global Controller (Age 54)

Has Merck & Co., Inc. been receiving favorable news coverage?

Press coverage about MRK stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & Co., Inc. earned a news and rumor sentiment score of 0.11 on Accern's scale. They also gave media coverage about the company an impact score of 46.87 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Merck & Co., Inc..

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.88%), Bank of New York Mellon Corp (1.43%), Morgan Stanley (0.59%), Macquarie Group Ltd. (0.55%), Boston Partners (0.54%) and Legal & General Group Plc (0.47%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rita A Karachun, Rochelle B Lazarus, Sanat Chattopadhyay, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Point72 Asset Management L.P., American Century Companies Inc., Natixis, Schroder Investment Management Group, MUFG Securities EMEA plc, Nomura Holdings Inc. and Canada Pension Plan Investment Board. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Rita A Karachun, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was purchased by a variety of institutional investors in the last quarter, including Senator Investment Group LP, Bank of Montreal Can, Janus Henderson Group PLC, Bank of New York Mellon Corp, Investec Asset Management LTD, Chevy Chase Trust Holdings Inc., Macquarie Group Ltd. and Glenmede Trust Co. NA. View Insider Buying and Selling for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $69.06.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $178.14 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  640 (Vote Outperform)
Underperform Votes:  673 (Vote Underperform)
Total Votes:  1,313
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel